Trials / Completed
CompletedNCT03245489
Anti-platelet + Pembro for H&N Tumors
Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | 200mg intravenous (IV) over 30 minutes |
| DRUG | Clopidogrel | 75mg/day oral |
| DRUG | acetylsalicylic acid | 81mg/day oral |
Timeline
- Start date
- 2018-03-06
- Primary completion
- 2023-11-20
- Completion
- 2024-11-20
- First posted
- 2017-08-10
- Last updated
- 2025-01-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03245489. Inclusion in this directory is not an endorsement.